First patients receive experimental cancer drug in early safety trial
NCT ID NCT07030712
Summary
This is the first human study of an experimental drug called MK-8294, designed to target certain advanced solid tumors. The main goal is to find the highest dose that is safe and tolerable for patients. It is enrolling about 67 adults with specific advanced cancers who have no other standard treatment options left.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0300)
RECRUITINGAmsterdam, North Holland, 1066 CX, Netherlands
Contact Phone: •••-•••-••••
-
Northwestern University ( Site 0101)
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-••••
-
Radboudumc ( Site 0301)
RECRUITINGNijmegen, Gelderland, 6525 GA, Netherlands
Contact Phone: •••-•••-••••
-
Rambam Health Care Campus ( Site 0201)
RECRUITINGHaifa, 3109601, Israel
Contact Phone: •••-•••-••••
-
Sheba Medical Center ( Site 0200)
RECRUITINGRamat Gan, 5265601, Israel
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.